Literature DB >> 17431760

Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations.

H M Verkooijen1, V C M Koot, G Fioretta, M van der Heiden, M E I Schipper, E Rapiti, P H M Peeters, J L Peterse, C Bouchardy.   

Abstract

BACKGROUND: In 2003, for the first time, US breast cancer incidence rates have fallen. Experts argue whether this is due to the reduced uptake of screening mammography or to lower use of Hormone Replacement Therapy (HRT). This study aims to disentangle the respective impact of screening and HRT on age-incidence rates and histology of breast cancer, by comparing two populations with comparably high levels of screening mammography, but with different prevalence of HRT.
METHODS: We included all invasive breast cancers recorded at the Geneva cancer registry (n = 4,909) and the Netherlands Cancer Registry (n = 152,428) between 1989-2003. We compared age-specific incidence rates and trends in histological subtyping between the two populations.
RESULTS: Between 1989-1991, incidence rates increased with age in both populations. In 2001-2003, women aged 60-64 years showed highest incidence rates in Geneva, while in the Netherlands incidence rates continued to increase with age. The annual increase in ductal cancer incidence was similar in the Netherlands (2.3%) and Geneva (2.5%), but the annual increase in lobular cancer was sharper in Geneva (10%) than in the Netherlands (5%).
CONCLUSION: The sharp differences in age distribution and histological subtyping of breast cancer between two European populations are not attributable to screening, since both populations have a high uptake of mammography screening. Since the prevalence of HRT use is very high in Geneva and rather low in the Netherlands, HRT may explain these discrepancies. However, other etiological factors and differences in histological assessment may also have played a role.

Entities:  

Mesh:

Year:  2007        PMID: 17431760     DOI: 10.1007/s10549-007-9554-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence.

Authors:  Diana S M Buist; Rod Walker; Erin J Aiello Bowles; Patricia A Carney; Stephen H Taplin; Tracy Onega; Karla Kerlikowske; Walter Clinton; Diana L Miglioretti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

2.  The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics.

Authors:  Mary Panjari; Robin Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Helen Farrugia; Susan R Davis
Journal:  Horm Cancer       Date:  2010-03-09       Impact factor: 3.869

3.  Decline in US breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

4.  Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Authors:  Agnès Fournier; Alban Fabre; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Franco Berrino; Françoise Clavel-Chapelon
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

5.  Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort.

Authors:  Sarah F Marshall; Christina A Clarke; Dennis Deapen; Katherine Henderson; Joan Largent; Susan L Neuhausen; Peggy Reynolds; Giske Ursin; Pamela L Horn-Ross; Daniel O Stram; Claire Templeman; Leslie Bernstein
Journal:  Breast Cancer Res       Date:  2010-01-08       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.